PKC activity assessment showed that its activity in the AD brain group was lower than the sham group, which was significant 10 days after Aβ injection, and this significant difference was observed 30 days after Aβ injection in platelet samples. The gene discussed is PRRT2; the disease is Alzheimer disease.